|
contents | america | ||||
| 6th Annual BIO-Windhover Conference The Biotechnology Industry Organization and Windhover Information Inc. are once again joining together to host the 6th Annual BIO-Windhover Conference – The Partnering Conference for Decision Makers, April 9-11, 2007 at the Ritz-Carlton, Washington, D.C. The BIO-Windhover Conference provides exclusive partnering opportunities for top-level pharmaceutical and biotechnology business development executives and CEOs. Using the conference's unique partnering software, attendees will have the opportunity to quickly identify and schedule meetings with prospective partners to discuss and negotiate deals or search company and delegate profiles and a database of licensing opportunities. This year's participants to date include delegations from Amgen, AstraZeneca, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb Co., Celera Genomics, Eisai, Eli Lilly & Co., Forest Laboratories, GlaxoSmithKline, Human Genome Sciences, Johnson & Johnson, LG Life Sciences, Merck, Otsuka Pharmaceutical, Pfizer Inc., Roche, Schering-Plough Corp., Takeda, and Wyeth, among others. The event will also feature two industry related plenary sessions. On Tuesday, April 10, Windhover Information's Managing Partner Roger Longman will moderate the panel session, "Hot In-Licensing Deals and the Rationale Behind Them." The panelists will be: Alan Crane, President & CEO, Tempo Pharmaceuticals, Inc., Denise Goode, Executive Transaction Director, Strategic Planning & Business Development, AstraZeneca, Annarie Lyles, Ph.D., Senior Vice President, Head of Business Development, Genmab, Kumar Srinivasan, Ph.D., MBA, Assistant Vice President, Licensing, Global Business Development, Wyeth Pharmaceuticals, Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co., Inc. write your comments about the article :: © 2007 Exhibition News :: home page |